BACKGROUND: Various factors have been reported to be useful for predicting future exacerbations. OBJECTIVE: This study was intended to determine a usefulness of a combination of a patient-based questionnaire, such as the Asthma Control Test (ACT) score with objective assessments, such as forced expiratory volume in 1 second (FEV(1)) and/or exhaled nitric oxide (FE(NO)), for predicting future exacerbations in adult asthmatics. METHODS: We therefore enrolled 78 subjects with mild to moderate asthma, who were clinically stable for 3 months who all had been regularly receiving inhaled steroid treatment. All subjects underwent a routine assessment of asthma control including the ACT score, spirometry, and FE(NO), and then were followed up until a severe exacerbation occurred. The predictors of an increased risk of severe exacerbation were identified and validated using decision trees based on a classification and regression tree (CART) analysis. The properties of the developed models were the evaluated with the area under the ROC curve (AUC) (95% confidence interval [CI]). RESULTS: The CART analysis automatically selected the variables and cut-off points, the ACT score <or=23 and FEV(1) <or= 91.8%, with the greatest capacity for discriminating future exacerbations within one year or not. When the probability was calculated by the likelihood ratio of a positive test (LP), the ACT score <or=23 was identified with a 60.3% probability, calculated by 1.82 of LP, whereas the combined ACT score <or=23 and the percentage of predicted FEV(1) <or= 91.8% were identified with an 85.0% probability, calculated by an LP score of 5.43, for predicting future exacerbation. CONCLUSION: These results demonstrated that combining the ACT score and percentage of predicted FEV(1), but not FE(NO,) can sufficiently stratify the risk for future exacerbations within one year.
BACKGROUND: Various factors have been reported to be useful for predicting future exacerbations. OBJECTIVE: This study was intended to determine a usefulness of a combination of a patient-based questionnaire, such as the Asthma Control Test (ACT) score with objective assessments, such as forced expiratory volume in 1 second (FEV(1)) and/or exhaled nitric oxide (FE(NO)), for predicting future exacerbations in adult asthmatics. METHODS: We therefore enrolled 78 subjects with mild to moderate asthma, who were clinically stable for 3 months who all had been regularly receiving inhaled steroid treatment. All subjects underwent a routine assessment of asthma control including the ACT score, spirometry, and FE(NO), and then were followed up until a severe exacerbation occurred. The predictors of an increased risk of severe exacerbation were identified and validated using decision trees based on a classification and regression tree (CART) analysis. The properties of the developed models were the evaluated with the area under the ROC curve (AUC) (95% confidence interval [CI]). RESULTS: The CART analysis automatically selected the variables and cut-off points, the ACT score <or=23 and FEV(1) <or= 91.8%, with the greatest capacity for discriminating future exacerbations within one year or not. When the probability was calculated by the likelihood ratio of a positive test (LP), the ACT score <or=23 was identified with a 60.3% probability, calculated by 1.82 of LP, whereas the combined ACT score <or=23 and the percentage of predicted FEV(1) <or= 91.8% were identified with an 85.0% probability, calculated by an LP score of 5.43, for predicting future exacerbation. CONCLUSION: These results demonstrated that combining the ACT score and percentage of predicted FEV(1), but not FE(NO,) can sufficiently stratify the risk for future exacerbations within one year.
Authors: Jonah S Zitsman; Paula Alonso-Guallart; Christopher Ovanez; Yojiro Kato; Joanna F Rosen; Joshua I Weiner; Raimon Duran-Struuck Journal: Comp Med Date: 2016 Impact factor: 0.982
Authors: Sonia Cajigal; Karen E Wells; Edward L Peterson; Brian K Ahmedani; James J Yang; Rajesh Kumar; Esteban G Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Pract Date: 2016-08-17
Authors: Albert M Levin; Hongsheng Gui; Natalia Hernandez-Pacheco; Mao Yang; Shujie Xiao; James J Yang; Samantha Hochstadt; Andrea J Barczak; Walter L Eckalbar; Dean Rynkowski; Lesly-Anne Samedy; Pui-Yan Kwok; Maria Pino-Yanes; David J Erle; David E Lanfear; Esteban G Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2018-10-24 Impact factor: 10.793
Authors: Francisco Javier Álvarez Gutiérrez; Marta Ferrer Galván; Juan Francisco Medina Gallardo; Marta Barrera Mancera; Beatriz Romero Romero; Auxiliadora Romero Falcón Journal: BMC Pulm Med Date: 2017-05-02 Impact factor: 3.317